Survodutide
Survodutide is a dual glucagon and GLP-1 receptor agonist co-developed by Zealand Pharma and Boehringer Ingelheim. Currently under clinical investigation, it shows tremendous promise in treating obesity and MASH (liver disease) by increasing energy expenditure and reducing appetite.
Verifying a batch
Match the batch code on the vial to a third-party certificate of analysis showing both purity and identity.
Search lab reports for this compound →How purity is tested →
Looking for Survodutide?
Join our next group buy to get verified quality at wholesale prices.
All compounds listed here are supplied for laboratory research use only and are not medicines, supplements, or products for human consumption.